Actively Recruiting
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Led by yuanli Zhao · Updated on 2019-09-04
200
Participants Needed
2
Research Sites
382 weeks
Total Duration
On this page
Sponsors
Y
yuanli Zhao
Lead Sponsor
P
Peking University International Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cerebral cavernous malformation (CCM)-related epilepsy (CRE) impairs the quality of life in patients with CCM. Patients could not always achieve seizure freedom after surgical resection of the lesion, suggesting an inadequate treatment and evaluation of the epileptogenic zone or network. Iron deposition in cerebral cavernous malformations has been postulated to play an important role in triggering CRE. Quantitative susceptibility mapping (QSM), as an optimal in vivo imaging technique to quantify iron deposition, is employed to analyze the iron quantity in CCM patients with epilepsy and further combined with brain structural and connectome analysis, to describe the difference between CCMs with and without epilepsy. In vivo biomarkers predicting CRE risk in CCM natural history and CRE control outcome after CCM surgical resection will be further identified to improve management strategy.
CONDITIONS
Official Title
Quantitative Susceptibility Biomarker and Brain Structural Property for Cerebral Cavernous Malformation Related Epilepsy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be between 18 and 70 years old
- Diagnosed with a single cerebral cavernous malformation
- Have not received prior treatment for the symptomatic lesion
You will not qualify if you...
- Have brain lesions or tumors other than cerebral cavernous malformation
- Have had previous brain surgery
- Have received prior brain irradiation
- Cannot or do not want to undergo research MRI scans
- Are pregnant or breastfeeding
- Are unable or unlikely to attend follow-up visits
- Have dementia or other progressive neurological diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100079
Actively Recruiting
2
Peking University International Hospital
Beijing, Beijing Municipality, China, 102206
Actively Recruiting
Research Team
L
Li Ma, MD, PhD
CONTACT
Y
Yuanli Zhao, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here